Efficacy of oral intake of a compound medical device in the treatment of laryngopharyngeal reflux disease: a clinical investigation and nasal cytological correlations

E. Maffezzoni, K. Luciano, F. Maffezzoni, S. Agostini, M. Notargiacomo

PDF(735 KB)
JBRHA
Journal of Biological Regulators and Homeostatic Agents ›› 2022, Vol. 36 ›› Issue (1) : 185-192. DOI: 10.23812/21-485-L
Letter

Efficacy of oral intake of a compound medical device in the treatment of laryngopharyngeal reflux disease: a clinical investigation and nasal cytological correlations

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2022, 36(1): 185-192 https://doi.org/10.23812/21-485-L

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
Article Options
  • PDF (56 views)
  • Full Text ( views)

Accesses

Citation

Detail
Sections
Recommended

Journal Info

About JBRHA
Indexing & Archiving
Editorial Board
Open Access
Copyright & License

For Authors

Submit
Instructions for Authors
Editorial Process
Article Processing Charge

For Reviewers

Online Review
Guidelines for Reviewers
Peer Review Process

Articles

Current Issue
Archives
Follow Us on
Copyright © 2023 Biolife Sas.
  • Disclaimer
    The statements, opinions and data contained in Journal of Biological Regulators and Homeostatic Agents are solely those of the individual authors and contributors and not of the journal and the editor(s). Journal of Biological Regulators and Homeostatic Agents stays neutral with regard to jurisdictional claims in published maps and insitutional affiliations.
    • 　　Terms & Conditions　　 Terms & Use　　　 Privacy Policy　

    /

    〈 〉